Imaging News and Research

RSS

New ultrasound pacemaker design promises minimal recovery time for cardiac patients

MIT engineers have developed a noninvasive pacemaker that stimulates the heart using ultrasound. The design could one day provide a surgery-free alternative to traditional cardiac implants.

2 Jun 2026

New magnetic particle imaging ensures precision cell therapy injection tracking

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers.

2 Jun 2026

New blood test tracks real time gene expression inside living brain tissue

Cell function is determined by how DNA is expressed into proteins. That process includes two main steps - transcription, when messenger RNA (mRNA) makes copies of active genes, and translation, when mRNA guides protein assembly.

2 Jun 2026

New portable PET technology guides procedures with real-time imaging

A newly developed portable, point-of-care PET technology can image any organ, delivering high-quality results to guide interventional procedures.

1 Jun 2026

Whole-body PET scans track metabolic recovery after weight-loss surgery

A novel PET imaging framework reveals that bariatric surgery impacts not only body weight, but also the metabolic function of multiple organs.

1 Jun 2026

New PET tracer offers a powerful tool for kidney cancer staging

A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC), according to early clinical research.

1 Jun 2026

Genetic testing finds breast cancer risks that standard screening models miss

Population-based pathogenic variant testing identified breast cancer susceptibility gene carriers who would often be missed by clinical risk models, even when polygenic risk scores were added. In the WISDOM Study analysis, fewer than 1% of high-penetrance variant carriers would have received the same high-risk screening recommendation using clinical plus polygenic risk alone.

1 Jun 2026

New PET radiotracer provides noninvasive diagnosis for primary aldosteronism

A new first-in-human study has validated a PET radiotracer that can effectively image overactive adrenal glands, offering an alternative to the highly invasive procedure currently utilized to diagnose primary aldosteronism.

1 Jun 2026

New PET radiotracer shows high accuracy for detecting clots in the legs and lungs

A novel PET radiotracer can accurately detect deep vein thrombosis in the legs and reveal whether clots have migrated to the lungs.

1 Jun 2026

Physics-informed machine learning enables continuous cuffless blood pressure monitoring

Blood pressure is a key metric of cardiovascular health, but standard methods for measuring it rely on occasional readings using inflatable cuffs, usually in a clinical setting.

1 Jun 2026

New PET imaging tracks tumor progression and cardiac inflammation during cancer therapy

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.

1 Jun 2026

PSMA PET detects high-risk prostate cancer bone metastases

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.

1 Jun 2026

New imaging method distinguishes inflammation from lung fibrosis

A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

New PET imaging approach may enable early CTE diagnosis

A first-in-class PET imaging approach can accurately detect a biomarker for chronic traumatic encephalopathy (CTE), a devastating neurodegenerative disease associated with repeated head impact.

31 May 2026

Predictive model helps tailor PSMA therapy for prostate cancer patients

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.

31 May 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

Physician groups welcome landmark overhaul of federal dispute process

The American Society of Anesthesiologists (ASA), American College of Emergency Physicians (ACEP) and American College of Radiology (ACR) today applauded the final Independent Dispute Resolution (IDR) Operations Rule under the No Surprises Act (NSA) released on May 28, commending federal agencies for their thoughtful and collaborative approach in addressing longstanding challenges and advancing a more functional, transparent dispute resolution system.

29 May 2026